A group of new and existing backers have provided cash to Galecto, based on research from the universities of Lund and Edinburgh.

US-based cancer and fibrosis treatment developer Galecto completed a $64m funding round on Friday backed by pharmaceutical firms Novo and Bristol Myers-Squibb (BMS). Soleus Capital and Eir Ventures co-led the round, while Cormorant Asset Management, Janus Henderson Investors, Hadean Ventures, Sphera, Asymmetry Capital Management, Canica, OrbiMed, Ysios Capital, HBM Healthcare Investments, Sunstone Capital, Seventure and…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.